17 results about "Apolipoprotein A1" patented technology

[Problems] The purpose of the present technology is to accurately detect cognitive impairment or risk thereof.[Solution] The present technology provides a cognitive impairment determination system comprising an information processing device that executes a determination step of determining presence or absence cognitive impairment or risk of cognitive impairment, based on amounts of the following biomarkers (a), (b), (c), (d), and (e) contained in a biological sample: (a) a biomarker consisting of an intact protein of Apolipoprotein A1 comprising an amino acid sequence represented by SEQ ID NO: 1, or a partial peptide thereof, (b) a biomarker consisting of an intact protein of Transthyretin comprising an amino acid sequence represented by SEQ ID NO: 2, or a partial peptide thereof, (c) a biomarker consisting of an intact protein of Complement C3 having an amino acid sequence represented by SEQ ID NO: 3, or a partial peptide thereof, (d) a biomarker Aβ1-40 consisting of a peptide having an amino acid sequence represented by SEQ ID NO: 4, and (e) a biomarker Aβ1-42 consisting of a peptide having an amino acid sequence represented by SEQ ID NO: 5.

The invention discloses a group of pyemia specific biomarkers and application thereof, and belongs to the field of medical detection.The biomarkers are formed by combination of alpha 1-microglobulin / Bikunin precursor protein and one or more of antithrombin III protein, apolipoprotein A1 or apolipoprotein H, according to the invention, seven core proteins, namely APOA1, APOH, AMBP, SERPINC1, F2, FGG and FGB, are screened from TMT proteomics of serum of a clinical hemorrhagic patient, and four more important proteins, namely APOA1, APOH, AMBP, SERPINC1, F2, FGG and FGB, are obtained by further screening the seven proteins in a hemorrhagic cell model and the clinical hemorrhagic patient. The four proteins are verified again in serum of a hemorrhagic mouse animal experiment and an expanded-scale clinical hemorrhagic patient, and the potential of the four core proteins as serum biomarkers for early diagnosis of hemorrhagic disease is determined.

The invention discloses a model for predicting the progression hepatic fibrosis risk of a WD long-term maintenance treatment patient and a design method thereof, and relates to the technical field of medical information, the prediction model comprises the following steps: an input module receives patient parameter indexes composed of sex (SEX), platelet (PLT), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (Apo-A1), laminin (LN) and copper cyanin (CER), and the input module receives the patient parameter indexes composed of sex (SEX), platelet (PLT), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (Apo-A1), laminin (LN) and copper cyanin (CER); the processing module obtains single scores corresponding to the seven independent risk factors, the single scores are added to obtain a total score, the prediction probability corresponding to the total score is the risk of the progression-stage hepatic fibrosis of the WD long-term maintenance treatment patient, and the prediction risk probability is output through the output module. The column diagram prediction model established by the invention has relatively high accuracy, and can be conveniently used for early recognition and risk prediction of progression-stage hepatic fibrosis of WD long-term maintenance treatment patients.

The present invention relates to a novel method of treating pulmonary emphysema in patients suffering from alpha-1 antitrypsin deficiency (AATD), a genetic disorder that causes low levels of alpha-1 antitrypsin (AAT), a protein that protects the lungs from damage by neutrophil elastase. The invention consists of aerosolizing nanoparticles composed of apolipoprotein A1 enriched with AAT (A1NP). The invention aims to deliver these nanoparticles directly to the lungs, where they can interact with the alveolar surface and modulate the inflammatory and proteolytic processes that lead to emphysema. In particular, the inventors report that said nanoparticles are not cytotoxic, have anti-inflammatory and anti-elastase properties, can cross alveolar epithelial cells, and are not immunogenic in mice.

RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID Nos: 1-1313 and compositions, methods, and uses thereof.

The application belongs to the technical field of medical detection, and discloses a biomarker for diagnosing hepatocellular carcinoma and application thereof. The biomarker comprises a combination of coding nucleic acids of alpha-1-microglobulin, vitronectin, apolipoprotein A1, fibrinogen gamma chain, fibrinogen alpha chain and albumin; and the coding nucleic acids comprise mRNA or cDNA. The application purifies CD147 positive extracellular vesicles from plasma, and performs PCR detection on mRNA of hepatocellular carcinoma biomarkers carried in the extracellular vesicles. A HCC Score diagnosis model is constructed based on detection results of the biomarkers, and has high diagnostic sensitivity and specificity for hepatocellular carcinoma, has great potential in screening of early hepatocellular carcinoma, and has important practical significance for early diagnosis of hepatocellular carcinoma.

Biomarkers for detecting cognitive dysfunction diseases and methods for detecting cognitive dysfunction diseases using the biomarkers are provided. A method for detecting cognitive dysfunction diseases comprising measuring one or more biomarkers for detecting cognitive dysfunction diseases selected from the following (a), (b), and (c) in a biological sample simultaneously or separately: (a) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of apolipoprotein A1 comprising the amino acid sequence represented by SEQ ID NO:1 or a partial peptide thereof; (b) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of transthyretin comprising the amino acid sequence represented by SEQ ID NO:2 or a partial peptide thereof; and (c) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of complement C3 comprising the amino acid sequence represented by SEQ ID NO:3 or a partial peptide thereof.

The invention discloses a serology-based rapid diagnosis method for juvenile tuberculosis. The invention provides an economical and efficient method for diagnosing tuberculosis of teenagers. Based on serum proteomics of clinically active teenager tuberculosis patients, a rapid tuberculosis diagnosis method based on serology is found. According to the present invention, through a variety of machine learning algorithms, the combination of the three proteins such as the apolipoprotein A1 (Apolipoprotein A-I, APOA1), the hemoglobin subunit alpha (Hemoglobin subunit alpha-1, HBA1) and the hemoglobin subunit beta (Hemoglobin subunit beta, HBB) has the highest accuracy and the highest sensitivity in the teenager tuberculosis diagnosis process, such that the combination can be adopted as the serological diagnosis marker of the teenager tuberculosis; the invention provides a new method for rapid diagnosis of juvenile tuberculosis.

This invention belongs to the field of biotechnology, specifically relating to a complex peptide for enhancing animal immunity and its preparation method. The complex peptide is composed of InflamBlock-9 peptide and ImmunoEnhance-7 peptide in a mass ratio of 3:1. InflamBlock-9 peptide reduces the excessive secretion of pro-inflammatory factors IL-1β, IL-6, and TNF-α by targeting and inhibiting the key protein IκB kinase (IKK) in the NF-κB signaling pathway. ImmunoEnhance-7 peptide promotes the synthesis of immunoglobulins IgG, IgA, and apolipoprotein A1 (Apo-A1) by activating the JAK-STAT signaling pathway. The combined use of these two peptides significantly reduces the levels of IL-1β, IL-6, and SAA in cat serum under stress (P<0.05) and increases the levels of IL-10, IgG, and Apo-A1 (P<0.05 or P<0.10), effectively alleviating excessive inflammatory response and improving immunosuppression. The preparation method of this invention achieves efficient peptide preparation through a dual prokaryotic and eukaryotic expression system. The process is controllable and low-cost, making it suitable for the development of functional pet foods or health products.

The invention belongs to the technical field of medical detection, and discloses a biomarker for diagnosing hepatocellular carcinoma and application of the biomarker. The biomarker comprises a combination of a coding nucleic acid of alpha-1-microglobulin, a coding nucleic acid of vitronectin, a coding nucleic acid of apolipoprotein A1, a coding nucleic acid of a fibrinogen gamma chain, a coding nucleic acid of a fibrinogen alpha chain and a coding nucleic acid of albumin; the coding nucleic acid comprises mRNA or cDNA. According to the invention, CD147 positive extracellular vesicles are purified from plasma, PCR detection is carried out on mRNA of an internally loaded hepatocellular carcinoma biomarker, and an HCC Score diagnosis model constructed by taking a detection result of the biomarker as a characteristic has relatively high diagnosis sensitivity and specificity on hepatocellular carcinoma, has great potential in early screening of liver cancer, and can be used for diagnosis of hepatocellular carcinoma. And the kit has important practical significance on early diagnosis of hepatocellular carcinoma.

The invention belongs to the technical field of biology, and particularly relates to a composite peptide capable of improving animal immunity and a preparation method of the composite peptide, and the composite peptide is formed by compounding InflamBlock-9 peptide and ImunoEnhance-7 peptide according to the mass ratio of 3: 1. Wherein the InflamBlock-9 peptide is used for reducing excessive secretion of proinflammatory factors IL-1beta, IL-6 and TNF-alpha through targeted inhibition of an NF-kappa B signal channel key protein Ikappa B kinase (IKK); the ImmunoEnhance-7 peptide is used for promoting the synthesis of immune globulins IgG (Immunoglobulin G) and IgA (Immunoglobulin A) and apolipoprotein A1 (Apo-A1) by activating a JAK-STAT (JavaScript Activated Amplification) signal channel. The combined use of the two can significantly reduce the levels (Plt, 0.05) of IL-1beta, IL-6 and SAA in the serum of cats in a stress state, improve the contents (Plt, 0.05 or Plt, 0.10) of IL-10, IgG and Apo-A1, and effectively relieve the inflammatory overexpression and improve the immunosuppression state. According to the preparation method, efficient preparation of the polypeptide is achieved through a prokaryotic and eukaryotic dual-expression system, the process is controllable, cost is low, and the preparation method is suitable for development of functional food or health care products for pets.

RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID NOs: 1-1313 and compositions, methods, and uses thereof.

The invention relates to a new non-invasive test making it possible to detect infection by the SARS-CoV-2 virus in a patient, using values of Apolipoprotein A1 alone or in combination with other markers.

The present invention relates to a peptide identified as SEQ ID NO: 1 for use in the manufacture of a medicament for treating a disease associated with the involvement of apolipoprotein A1 (Apo-A1) or transthyretin (TTR). In particular, the peptide may be useful in the treatment of diseases characterized by the involvement of lipid homeostasis or TTR stability. The present invention also relates to a method for treating a disease associated with the involvement of Apo-A1 or TTR, the method comprising administering a therapeutically effective amount of a pharmaceutical composition comprising the peptide identified as SEQ ID NO: 1.

The application discloses a set of sepsis-specific biomarkers and application thereof, and belongs to the medical detection field.The marker is composed of the combination of alpha 1-microglobulin / Bikunin precursor protein and one or more of antithrombin III protein, apolipoprotein A1 or apolipoprotein H.Through TMT proteomics screening of serum of clinical sepsis patients, seven core proteins, APOA1, APOH, AMBP, SERPINC1, F2, FGG and FGB, are screened out.Further screening of the seven proteins in a sepsis cell model and clinical sepsis patients obtains four more important proteins, APOA1, APOH, AMBP and SERPINC1.The four proteins are verified again in a sepsis mouse animal experiment and serum of clinical sepsis patients on a large scale, and the potential of the four core proteins as serum biomarkers for early diagnosis of sepsis is determined.

The invention discloses an apolipoprotein A1 fusion protein for preventing and treating atherosclerosis as well as a preparation method and application of the apolipoprotein A1 fusion protein, and belongs to the technical field of biological medicines. The method specifically comprises the following steps: cloning an apolipoprotein A1 gene to a pET28a expression vector, and transforming escherichia coli for expression; the expression product is purified, purification conditions are optimized, and the physicochemical properties of the expression product are represented by related means. In addition, the invention also relates to application of the fusion protein in the cellular level, including cytotoxicity experiment, and evaluation of protein uptake capability and cholesterol reverse transport capability of cells. Experimental results show that the prepared apolipoprotein A1 fusion protein can specifically target the liver, the atherosclerotic plaque area is remarkably reduced, and the apolipoprotein A1 fusion protein has important application potential in prevention and treatment of atherosclerosis.

The present application relates to the field of food and / or medicine technology, and discloses a hypolipidemic composition, a preparation method and application thereof.The hypolipidemic composition comprises Echium seed oil, Nigella seed oil and safflower seed oil.The present application uses specific natural substances, i.e.Echium seed oil, Nigella seed oil and safflower seed oil, as the functional components, and forms a natural composition which can significantly reduce total cholesterol and triglyceride and increase the content of serum apolipoprotein A1, and has obvious hypolipidemic effect, and can be applied to the development and preparation of hypolipidemic medicine and food, especially health food.